Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note

Novo Nordisk stock fell 2.02% to $41.67, underperforming the S&P 500's 0.45% decline. The stock has depreciated 6.96% over the past month. The company is expected to report lower earnings (down 21.57% YoY) and slightly lower revenue (down 2.18% YoY) in its upcoming earnings disclosure. Despite recent positive estimate revisions of 3.45%, the stock holds a Zacks Rank of #3 (Hold) with a Forward P/E of 12.05, trading at a discount to its industry average.